Craig Thompson Chief Executive Officer

Craig has over 25 years of experience in biotech and the pharmaceutical industry. He has experience at Merck, Pfizer and several biotech companies including Trius. Prior to joining Cerevance, he was President and CEO of Neurana Pharmaceuticals.

Nathaniel Heintz, Ph.D. Chief Scientific Advisor

Nat is the James & Marilyn Simons Professor of Molecular Biology at The Rockefeller University, an Investigator at the Howard Hughes Medical Institute, and a member of the National Academy of Sciences.

Mark Carlton, Ph.D. Chief Scientific Officer

Mark has over 25 years of experience in academia, biotech and the pharmaceutical industry. He was a co-founder of Paradigm Therapeutics and most recently served as President and CSO of Takeda Pharmaceutical's Cambridge UK site.

Ottavio V. Vitolo, M.D. Chief Medical Officer

Ottavio is a neuropsychiatrist with more than 20 years of experience in translational research and clinical development in common and rare neurological and psychiatric conditions.
He served in roles of increasing responsibility in pharma and biotech companies including Shire, Pfizer, Homology Medicines, and Relmada Therapeutics and Alcyone Therapeutics, where he was head of R&D and CMO. Ottavio also maintains a clinical practice at MGH in Boston and a teaching position at Harvard Medical School.

Robert Middlebrook Chief Financial Officer

Rob previously served as CFO of Envoy Therapeutics and as Chief Corporate Development Officer of Perlegen Sciences. Earlier, Rob held a number of senior leadership roles with Fidelity Investments including Chief Investment Officer of the $28 billion Managed Income Group and Head Trader of the $26 billion Municipal Money Market Group.

Carrie Ann Cook Chief Business Officer

Carrie has over 22 years of experience in the biotech and pharmaceutical industry. She has held a number of positions of increasing responsibility in business development and marketing at Merck KGaA, Baxter, Novartis and Takeda. She most recently worked as SVP, Global Head of Business Development at CANbridge Pharmaceuticals.

Lee Dawson, Ph.D. Vice President,

Lee has over 25 years of experience in biotech and the pharmaceutical industry. He has held positions of increasing responsibility within the various neuroscience research functions at Wyeth Research, GlaxoSmithKline, and Eisai. Prior to joining Cerevance, he was VP of CNS at Astex / Otsuka Pharmaceuticals in Cambridge UK.

Roland Bürli, Ph.D. Vice President,
Drug Discovery

Roland brings more than 20 years of drug discovery experience, having worked in large pharma, biotech and the CRO sectors. Prior to joining Cerevance, he was Senior Director and Head of Medicinal Chemistry of the Neuroscience group at AstraZeneca.

Xiao Xu, Ph.D. Director, Computational Discovery

Xiao is a co-founder of Cerevance and co-developed the NETSseq technology platform used within the company in her postdoctoral work with Nat Heintz at The Rockefeller University. Her graduate work at Stanford focused on gene expression networks in aging.

Justin Powell, Ph.D. Director, Bioinformatics

Justin has over 18 years of experience leading bioinformatics and IT in both biotech and large pharma. Prior to joining Cerevance he was Head of Bioinformatics and IT at Takeda Cambridge.

Nicola Brice, Ph.D. Director, Neuroscience

Nicola has over 15 years of experience in biotech and the pharmaceutical industry with a focus on neuroscience. She has led multiple programs from concept to late-stage pre-clinical development. Prior to Cerevance, Nicola headed the psychiatry team at Takeda Cambridge.

Keith Page, Ph.D. Director, Neuroanatomy

Keith is a neuroanatomist with over 25 years CNS research, human tissue and tissue banking experience in industry. He has held doctoral positions in Massachusetts General Hospital and University of Cambridge MRC Centre for Brain Repair.

Naidong Ye, Ph.D. Vice President and Head of CMC

Naidong has over 25 years of pharmaceutical experience in CMC activities ranging from early development to commercialization planning. He has held positions of increasing responsibilities in several companies including Nycomed, ViroPharma, Vela, Pharmos and AstraZeneca. Prior to joining Cerevance, he was Vice President of CMC at Millendo Therapeutics.


Nathaniel Heintz, Ph.D.

James and Marilyn Simons Professor of Molecular Biology
The Rockefeller University
Investigator, Howard Hughes Medical Institute
Member, National Academy of Sciences

Tetsuyuki Maruyama, Ph.D.

Executive Director, Alzheimer's Disease Data Initiative
Former Chief Scientific Officer at Dementia Discovery Fund
Previously Head of Global Drug Discovery at
Takeda Pharmaceutical Company

Jeremy Nathans, M.D., Ph.D.

Professor of Molecular Biology and Genetics,
Neuroscience, and Ophthalmology
Johns Hopkins University School of Medicine
Investigator, Howard Hughes Medical Institute
Member, National Academy of Sciences

William J. Ray, Ph.D.

Director, The Neurodegeneration Consortium
Institute Head, Neuroscience, University of Texas
MD Anderson Cancer Center; previously led
CNS Research and Biology at Takeda, Envoy and Merck

James Summers, Ph.D.

Former Vice President, Neuroscience Research
at AbbVie; previously Divisional Vice President
of Advanced Technology at Abbott

Board of Directors

Brad Margus Executive Chairman Cerevance
Craig Thompson Chief Executive Officer Cerevance
Steve Hitchcock, Ph.D. Global Head of Research Takeda Pharmaceuticals
Jason Lettmann General Partner Lightstone Ventures
Laurence Barker, Ph.D. Chief Business Officer Dementia Discovery Fund
Aoife Brennan, M.B., B.Ch. Chief Executive Officer Synlogic
Matthias Kleinz, DVM, Ph.D. VP, Translational Programs UPMC Enterprises
David Lubner Independent Director
Mike Poole, M.D., FACP Senior Advisor RBNC Therapeutics


Lightstone Ventures is a premier therapeutic-oriented life science venture fund founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures and Morgenthaler.

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.

GV provides venture capital funding to bold new companies. Across the fields of life science, enterprise technology, consumer products and services, and frontier technology, GV's portfolio companies aim to improve lives and transform industries.

The Dementia Discovery Fund (DDF) is a venture capital fund that invests in projects and companies to discover and develop novel, effective disease-modifying therapeutics for dementia. Seven leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, Woodford Investment Management via Woodford Patient Capital Trust (WPCT), the UK’s Department of Health and Social Care and the charity Alzheimer’s Research UK among others have invested in the DDF.

UPMC Enterprises is the innovation, commercialization, and venture capital arm of UPMC, a $21 billion health care provider and insurer based in Pittsburgh. With an emphasis on translational science and digital solutions, UPMC Enterprises provides its portfolio companies and partners with capital, connections and resources to develop solutions to health care’s most complex problems. Working in close collaboration with innovators from UPMC and the University of Pittsburgh Schools of the Health Sciences, as well as others worldwide, UPMC Enterprises strives to accelerate science from the bench to the bedside.

Foresite Capital funds visionary healthcare entrepreneurs. With approximately $3 billion in assets under management, Foresite Capital has a team of clinical scientists, engineers, analysts and partners who support and guide companies at all stages of their life cycles. The firm is headquartered in San Francisco with an office in New York. For more information visit

In the fall of 2011, Eli founded his fast-growing growth equity fund in the equally fast growing sector of Life Sciences handily outperforming a sector-wide upswing. Casdin Capital's strategy and success lies in its deep fundamental research and participation in all aspects of the life science revolution; from diagnostics to information systems through to molecular medicines into industrial biotech applications. As Casdin often points out, genomics is a data-driven paradigm shift that is fundamentally reshaping the entire healthcare and life science industry, much as Silicon Valley and the semi-conductor reshaped our social and commercial lives, creating a diversity of investment opportunities along the way.

Dolby Family Ventures is an early stage venture firm focused on building great technology and life sciences companies. We partner with best-in-class innovators and strong investment syndicate partners. The fund honors the legacy of Ray Dolby and his commitment to entrepreneurs and their vision to solve the world's toughest problems. The life science investment focus centers on novel disease modifying therapeutics for Alzheimer’s disease, clinical depression, and neurostimulation therapies.

Technologist, business leader and philanthropist; co-founder of Microsoft Corporation.